Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INZY SEC filings page on Stock Titan compiles U.S. Securities and Exchange Commission documents historically filed by Inozyme Pharma, Inc., which traded on the Nasdaq Global Select Market under the symbol INZY before its acquisition by BioMarin Pharmaceutical Inc. These filings trace Inozyme’s life cycle as a public company, from its status as a clinical-stage biopharmaceutical issuer through its change of control, delisting, and deregistration.
Key transaction-related filings include a Form 8-K dated July 1, 2025, reporting the completion of BioMarin’s acquisition of Inozyme pursuant to an Agreement and Plan of Merger. This filing explains that a BioMarin subsidiary merged with and into Inozyme, with Inozyme continuing as the surviving corporation and becoming a wholly owned subsidiary of BioMarin. The same Form 8-K describes the tender offer at $4.00 per share in cash and the subsequent conversion of remaining shares into the right to receive the same consideration.
For trading status, a Form 25 filed on July 1, 2025, by Nasdaq Stock Market LLC documents the removal of Inozyme’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A Form 15 filed on July 11, 2025, then certifies the termination of registration of Inozyme’s common stock under Section 12(g) and the suspension of its duty to file periodic reports under Sections 13 and 15(d). Together, these filings confirm that INZY is a delisted and deregistered security.
Earlier periodic and current reports, such as Forms 10-K, 10-Q, and 8-K referenced in Inozyme’s press releases, provide additional context on the company’s clinical-stage operations, including its focus on the PPi-Adenosine Pathway, development of INZ-701 for ENPP1 and ABCC6 Deficiencies, and financial position prior to the acquisition. While those documents are accessed directly through the SEC’s EDGAR system, this page highlights the most material items for understanding INZY’s regulatory history.
Stock Titan enhances access to these filings with AI-powered summaries that explain the purpose and implications of each document in plain language. Users can quickly see how specific Forms 8-K relate to the merger and delisting, how the Form 25 and Form 15 altered Inozyme’s reporting obligations, and how the company’s disclosures fit into the broader narrative of its transition from an independent public issuer to a BioMarin subsidiary. This makes the INZY filings page a practical resource for anyone researching historical corporate actions, listing status changes, and the regulatory record associated with Inozyme Pharma’s former public listing.
Inozyme Pharma, Inc. (INZY) Schedule 13D/A shows that Pivotal-related reporting persons tendered an aggregate of 4,494,851 shares of common stock in a tender offer at $4.00 per share, which were accepted by the offering party, BioMarin Pharmaceutical Inc., at 11:59 p.m. ET on June 30, 2025. Following settlement of the offer on July 1, 2025, the reporting persons ceased to be beneficial owners of more than 5% of Inozyme common stock. The filing updates the cover page ownership rows to reflect 0 shares beneficially owned and 0% ownership for each reporting person.
Inozyme Pharma, Inc. has a Schedule 13G/A filing in which Beryl Capital entities and David A. Witkin report zero beneficial ownership of the company’s common stock, representing 0% of the class. The filers expressly disclaim beneficial ownership except for any pecuniary interest and note Beryl’s role as an investment adviser and general partner and Mr. Witkin’s role as a control person.
The filing includes certifications that any securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The submission is informational and does not report a material ownership stake.
Inozyme Pharma, Inc. has a Schedule 13G/A filed on behalf of a reporting group that includes Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP, Mark Bussard and Kris Jenner. The filing identifies the reporting structure: Rock Springs Capital Management LP acts as investment manager, Rock Springs Capital LLC is the general partner, and Mark Bussard and Kris Jenner each own 50% of the management company.
The filing discloses an aggregate beneficial ownership of 0 shares, representing 0% of the class; sole and shared voting and dispositive powers are all reported as 0. Signatories certify the securities were not acquired to change or influence control, and a joint filing statement commits the parties to file amendments on behalf of all undersigned.
Adage Capital Management, L.P., together with principals Robert Atchinson and Phillip Gross, filed an Amendment to Schedule 13G for Inozyme Pharma, Inc. (INZY). The filing reports 0.00 shares beneficially owned and 0% of the class, with sole and shared voting and dispositive power all shown as 0. The issuer's principal executive office is listed at 321 Summer Street, Suite 400, Boston, MA, and the reporting persons' business address is 200 Clarendon Street, 52nd Floor, Boston, MA. Signatures dated 08/12/2025 certify the information and state the securities were not acquired to influence control.
Form 4 Overview – Inozyme Pharma, Inc. (INZY)
This Form 4 discloses that Sanjay Subramanian, the company’s Senior Vice President, Chief Financial Officer and Head of Business Development, no longer holds any equity interests in Inozyme Pharma following the closing of a cash-only merger with BioMarin Pharmaceutical Inc. on 1 July 2025.
- Merger mechanics: BioMarin’s wholly-owned Incline Merger Sub completed a tender offer and subsequent merger, paying $4.00 in cash per Inozyme common share (the “Merger Consideration”).
- Common shares: 39,701 shares held by the reporting person were tendered for the $4.00 cash consideration.
- Restricted Stock Units (RSUs): 38,500 RSUs automatically accelerated, vested and were cancelled for a cash payment of $4.00 per underlying share.
- Stock options: A total of 460,000 options with strike prices of $3.96, $3.30 and $1.06 were fully vested and converted into the right to receive the intrinsic value (cash equal to $4.00 minus the option’s exercise price) per underlying share.
- Post-merger ownership: After these transactions, the reporting person reports zero derivative or non-derivative securities, reflecting the company’s transition to a wholly-owned BioMarin subsidiary.
The filing formally documents insider disposition of securities pursuant to the merger agreement and confirms that Inozyme’s public equity has effectively been cashed out at the specified price.
Form 4 highlights: Inozyme Pharma, Inc. (INZY) Chief Operating Officer Matthew Winton filed a Form 4 on 3 July 2025 reporting the cash disposal of all of his equity holdings in connection with the company’s merger with BioMarin Pharmaceutical Inc.
- Merger mechanics: BioMarin, through Incline Merger Sub, completed a cash tender offer and subsequent merger on 1 July 2025, paying $4.00 per INZY share. Inozyme is now a wholly-owned subsidiary of BioMarin.
- Common shares: 21,743 shares owned directly by the reporting person were tendered for the $4.00 cash consideration.
- Restricted Stock Units: 41,500 RSUs automatically accelerated, vested and were cancelled for a cash payment of $4.00 per underlying share.
- Stock options: 145,000 options with a $1.06 exercise price vested and were cashed out for the intrinsic value ( $4.00 – $1.06 ) per share.
- Following these transactions, the insider reports zero remaining beneficial ownership of INZY securities.
The filing confirms that the equity portion of the merger consideration has been delivered and that insider equity has been fully settled in cash, signalling the practical completion of the acquisition.
Form 4 Overview: The filing details the final disposition of Inozyme Pharma, Inc. (INZY) equity held by director Axel Bolte in connection with the closing of BioMarin Pharmaceutical’s all-cash acquisition of the company on 1 July 2025.
- Common stock: 423,926 shares tendered and converted into cash at $4.00 per share, the agreed Merger Consideration.
- Stock options: • 234,176 options (exercise $2.02, exp. 6/19/2029) and • 159,187 options (exercise $2.77, exp. 4/22/2030) were automatically accelerated, cancelled and cashed out for the intrinsic value (Merger Consideration minus exercise price) per option share.
- After the transactions, the reporting person holds zero INZY securities; Inozyme is now a wholly-owned subsidiary of BioMarin and will cease public trading.
Investor takeaway: The Form 4 confirms that the merger has reached the final settlement stage, signalling the end of INZY as a standalone public equity and locking in the previously announced $4.00 cash payment for all former shareholders.
Inozyme Pharma, Inc. (INZY) — Insider Form 4 Overview
CEO & Chairman Douglas A. Treco filed a Form 4 detailing the automatic disposition of his entire equity stake following the closing of Inozyme’s merger with BioMarin Pharmaceutical Inc. on 1 July 2025. Under the Agreement and Plan of Merger dated 16 May 2025, BioMarin’s wholly owned Incline Merger Sub acquired all outstanding Inozyme shares for $4.00 cash per share.
- Common stock: 43,861 shares were tendered at $4.00, eliminating Treco’s direct share ownership.
- Restricted stock units: 150,000 RSUs automatically accelerated, vested, and converted to a $4.00 cash payout per underlying share.
- Stock options: 86,979 options (exercise $2.77) and 400,000 options (exercise $1.06) vested and were cancelled in exchange for the cash spread between the $4.00 consideration and each strike price.
Following the transactions, Treco reports zero remaining beneficial ownership, reflecting Inozyme’s status as a wholly owned BioMarin subsidiary. The filing is largely procedural, confirming final insider settlement terms aligned with the previously announced merger.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
